Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities

Souza-Tarla, Caroline D.; Uzuelli, Juliana A.; Machado, Alcyone Artioli; Gerlach, Raquel Fernanda; Tanus‐Santos, Jose E.

doi:10.1016/j.clinbiochem.2005.02.010

Cited by 108 publications

(66 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…41,42 This assay allows the identification of the pro forms of MMP-2 and MMP-9. 43 Briefly, plasma samples were subjected to electrophoresis on 7% SDS-PAGE co-polymerized with gelatin (1%) as the substrate.…”

Section: Sds-polyacrylamide Gel Electrophoresis (Page) Gelatin Zymogrmentioning

confidence: 99%

A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients

et al. 2009

View full text Add to dashboard Cite

We examined whether two functional polymorphisms (g.À1562C4T and g.À90(CA)14-24) in the matrix metalloproteinase (MMP)-9 gene or MMP-9 haplotypes affect the circulating levels of pro-MMP-9 and pro-MMP-9/TIMP-1 (tissue inhibitor of metalloproteinase-1) ratios in AIDS patients, and modulate alterations in these biomarkers after highly active antiretroviral therapy (HAART). We studied 82 patients commencing HAART. Higher pro-MMP-9 concentrations and pro-MMP-9/TIMP-1 ratios were found in CT/TT patients compared with CC patients. HAART decreased pro-MMP-9 levels and pro-MMP-9/TIMP-1 ratios in CT/TT patients, it did not modify pro-MMP-9 levels and it increased pro-MMP-9/TIMP-1 ratios in CC patients. The g.À90(CA)14-24 polymorphism, however, produced no significant effects. Moreover, we found no significant differences in HAARTinduced changes in plasma pro-MMP-9, TIMP-1 and pro-MMP-9/TIMP-1 ratios when different MMP-9 haplotypes were compared. These findings suggest that the g.À1562C4T polymorphism affects pro-MMP-9 levels in patients with AIDS and modulates the alterations in pro-MMP-9 levels caused by HAART, thus possibly affecting the risk of cardiovascular complications.

show abstract

Section: Sds-polyacrylamide Gel Electrophoresis (Page) Gelatin Zymogrmentioning

confidence: 99%

A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients

et al. 2009

View full text Add to dashboard Cite

show abstract

“…10 No question is of greater interest to the clinicians dealing with breast diseases than the differentiation of BC subtypes through the determination of biomolecular markers useful for BC diagnosis and prognosis. Although the identification of the best source between plasma and serum for surrogate biomarkers is a matter of strenuous efforts and debate, [11][12][13][14][15][16][17] the scientific interest in the measurement of MMP in plasma/serum continues to mount, enhancing their promising development as reliable biomarkers.…”

mentioning

confidence: 99%

Gelatinase concentrations and zymographic profiles in human breast cancer: Matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: The coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum

Mannello

Tonti

2007

Intl Journal of Cancer

View full text Add to dashboard Cite

“…4,5 When evaluating the immunoreactive protein by ELISA assay, it should not equate with the assay of measuring the activities of MMP-9. [6][7][8] The source of circulating MMP-9 whether it is measured from serum or plasma is not easy to define. In our study, however, we were also able to show that there is a statistically significant correlation between the serum level of MMP-9 immunoreactive protein and MMP-9 immunohistochemical staining in primary tumors of HNSCC.…”

Section: Dear Sirmentioning

confidence: 99%

Reply to: Serum samples should not be used to access circulating matrix metalloproteinase‐9 levels as a prognostic marker of disease

Ruokolainen

Turpeenniemi‐Hujanen

2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Dear Sir,We thank Tanus-Santos and Gerlach for the special interest to our work regarding the serum matrix metalloproteinase-9 as a prognostic marker in head and neck squamous cell carcinoma 1 .In our study, we demonstrated that high preoperative serum MMP-9 levels were linked with poor cause-specific as well as poor relapse-free survival in head and neck squamous cell carcinoma patients.1 The median serum level for MMP-9 immunoreactive protein of HNSCC patients was 89.9 ng/ml and the mean value was 115.2 ng/ml. Additionally, we demonstrated that the MMP-9 levels in 44 healthy controls were lower, median 55.6 ng/ml, mean 69.7 ng/ml (p < 0.001). The levels of MMP-9 immunoreactive protein in our study are thus clearly in line with studies published previously concerning MMP-9 serum levels in HNSCC patients 2,3 and the MMP-9 levels in controls equal the control plasma levels in study by Jung et al. 4 Moreover, Jung et al.4 have compared the serum and plasma levels of MMP-9 immunoreactive protein among controls using serum samples collected with or without tubes based on additives with clot activator. In our study, the serum samples were all so-called native serum samples i.e., collected with tubes with no additives. We also want to point out the fact that in our study all samples have been handled in consistent method. This fact would have been very important to add to the Material and Methods section and we are very grateful to have this opportunity to clarify the issue. In general, the pre-analytical conditions and methodological issues are essential when assessing MMP-9 in clinical samples. 4,5 When evaluating the immunoreactive protein by ELISA assay, it should not equate with the assay of measuring the activities of MMP-9. [6][7][8] The source of circulating MMP-9 whether it is measured from serum or plasma is not easy to define. In our study, however, we were also able to show that there is a statistically significant correlation between the serum level of MMP-9 immunoreactive protein and MMP-9 immunohistochemical staining in primary tumors of HNSCC.

show abstract

Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities

Cited by 108 publications

References 18 publications

A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients

A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients

Reply to: Serum samples should not be used to access circulating matrix metalloproteinase‐9 levels as a prognostic marker of disease

Contact Info

Product

Resources

About